224 related articles for article (PubMed ID: 21038110)
1. Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen.
Parekh C; Jubran R; Erdreich-Epstein A; Panigrahy A; Bluml S; Finlay J; Dhall G
J Neurooncol; 2011 Jul; 103(3):673-80. PubMed ID: 21038110
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab in recurrent high-grade pediatric gliomas.
Narayana A; Kunnakkat S; Chacko-Mathew J; Gardner S; Karajannis M; Raza S; Wisoff J; Weiner H; Harter D; Allen J
Neuro Oncol; 2010 Sep; 12(9):985-90. PubMed ID: 20363768
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.
Zuniga RM; Torcuator R; Jain R; Anderson J; Doyle T; Ellika S; Schultz L; Mikkelsen T
J Neurooncol; 2009 Feb; 91(3):329-36. PubMed ID: 18953493
[TBL] [Abstract][Full Text] [Related]
4. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab.
Quant EC; Norden AD; Drappatz J; Muzikansky A; Doherty L; Lafrankie D; Ciampa A; Kesari S; Wen PY
Neuro Oncol; 2009 Oct; 11(5):550-5. PubMed ID: 19332770
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma.
Verhoeff JJC; Lavini C; van Linde ME; Stalpers LJA; Majoie CBLM; Reijneveld JC; van Furth WR; Richel DJ
Ann Oncol; 2010 Aug; 21(8):1723-1727. PubMed ID: 20064829
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
[TBL] [Abstract][Full Text] [Related]
7. Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival.
Chen C; Huang R; MacLean A; Muzikansky A; Mukundan S; Wen PY; Norden AD
J Neurooncol; 2013 Nov; 115(2):267-76. PubMed ID: 23974656
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab use for recurrent high-grade glioma at McGill University Hospital.
Sahebjam S; Garoufalis E; Guiot MC; Muanza T; Del Maestro R; Petrecca K; Sharma R; Kavan P
Can J Neurol Sci; 2013 Mar; 40(2):241-6. PubMed ID: 23419575
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.
Gururangan S; Fangusaro J; Poussaint TY; McLendon RE; Onar-Thomas A; Wu S; Packer RJ; Banerjee A; Gilbertson RJ; Fahey F; Vajapeyam S; Jakacki R; Gajjar A; Goldman S; Pollack IF; Friedman HS; Boyett JM; Fouladi M; Kun LE
Neuro Oncol; 2014 Jan; 16(2):310-7. PubMed ID: 24311632
[TBL] [Abstract][Full Text] [Related]
10. Retrospective study of nivolumab for patients with recurrent high grade gliomas.
Mantica M; Pritchard A; Lieberman F; Drappatz J
J Neurooncol; 2018 Sep; 139(3):625-631. PubMed ID: 29779086
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma.
Drappatz J; Lee EQ; Hammond S; Grimm SA; Norden AD; Beroukhim R; Gerard M; Schiff D; Chi AS; Batchelor TT; Doherty LM; Ciampa AS; Lafrankie DC; Ruland S; Snodgrass SM; Raizer JJ; Wen PY
J Neurooncol; 2012 Mar; 107(1):133-8. PubMed ID: 21984064
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab-containing regimen in relapsed/progressed brain tumors: a single-institution experience.
Schiavetti A; Varrasso G; Mollace MG; Dominici C; Ferrara E; Papoff P; Di Biasi C
Childs Nerv Syst; 2019 Jun; 35(6):1007-1012. PubMed ID: 30903281
[TBL] [Abstract][Full Text] [Related]
14. FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan.
Colavolpe C; Chinot O; Metellus P; Mancini J; Barrie M; Bequet-Boucard C; Tabouret E; Mundler O; Figarella-Branger D; Guedj E
Neuro Oncol; 2012 May; 14(5):649-57. PubMed ID: 22379188
[TBL] [Abstract][Full Text] [Related]
15. Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas.
Hundsberger T; Brügge D; Putora PM; Weder P; Weber J; Plasswilm L
J Neurooncol; 2013 Mar; 112(1):133-9. PubMed ID: 23314822
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas.
Seystahl K; Wiestler B; Hundsberger T; Happold C; Wick W; Weller M; Wick A
Eur Neurol; 2013; 69(2):95-101. PubMed ID: 23182901
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival.
Narayana A; Kelly P; Golfinos J; Parker E; Johnson G; Knopp E; Zagzag D; Fischer I; Raza S; Medabalmi P; Eagan P; Gruber ML
J Neurosurg; 2009 Jan; 110(1):173-80. PubMed ID: 18834263
[TBL] [Abstract][Full Text] [Related]
18. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan.
Packer RJ; Jakacki R; Horn M; Rood B; Vezina G; MacDonald T; Fisher MJ; Cohen B
Pediatr Blood Cancer; 2009 Jul; 52(7):791-5. PubMed ID: 19165892
[TBL] [Abstract][Full Text] [Related]
19. Treatment with bevacizumab plus carboplatin for recurrent malignant glioma.
Thompson EM; Dosa E; Kraemer DF; Neuwelt EA
Neurosurgery; 2010 Jul; 67(1):87-93. PubMed ID: 20559095
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
Vredenburgh JJ; Desjardins A; Herndon JE; Dowell JM; Reardon DA; Quinn JA; Rich JN; Sathornsumetee S; Gururangan S; Wagner M; Bigner DD; Friedman AH; Friedman HS
Clin Cancer Res; 2007 Feb; 13(4):1253-9. PubMed ID: 17317837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
